title: Protease inhibitors and adverse birth outcomes: is progesterone the missing piece to the puzzle?
authors.affiliation: Departments of Internal Medicine and Pediatrics, Massachusetts General Hospital Department of Immunology and Infectious Diseases, Harvard School of Public Health.
authors.forename: Kathleen M
authors.initials: KM
authors.lastname: Powis
authors.affiliation: Department of Immunology and Infectious Diseases, Harvard School of Public Health Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
authors.forename: Roger L
authors.initials: RL
authors.lastname: Shapiro
mesh_terms: D000818:Animals; D005260:Female; D047109:Fetal Development / Q000187:drug effects*; D005317:Fetal Growth Retardation / Q000139:chemically induced*; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy*; D011374:Progesterone / Q000378:metabolism*
chemical_list: D017320:HIV Protease Inhibitors; D011374:Progesterone
keywords: HIV; pregnancy outcomes; progesterone; protease inhibitors